Abstract
A vaccine against pneumococci may be the best approach to overcoming the increasing incidence of multidrug-resistant (MDR) strains of this organism. Other approaches are also under investigation, including the use of multimeric α-lactalbumin and the new cephalosporin cefepime. However, increasing the use of oral cephalosporins may exacerbate the problem, according to Professor Keith Klugman from the University of Witwatersrand, Johannesburg, South Africa. The views of Professor Klugman and other leading specialists in this field were presented at the 7th International Congress of Infectious Disease [Hong Kong; June 1996].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
